ABKEN HINRICH has a total of 12 patent applications. Its first patent ever was published in 1996. It filed its patents most often in WIPO (World Intellectual Property Organization), Germany and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are INST OF VIROLOGY SLOVAK ACADEM, RAPOPORT BASIL and BRINKMANN ULRICH.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 4 | |
#2 | Germany | 3 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | Australia | 1 | |
#5 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Measuring microorganism processes | |
#5 | Microorganisms | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Abken Hinrich | 11 |
#2 | Schinkoethe Timo | 2 |
#3 | Hombach Andreas | 2 |
#4 | Schinkothe Timo | 1 |
Publication | Filing date | Title |
---|---|---|
EP3169703A1 | Chimeric antigen receptor and its use | |
DE10046318A1 | Detecting tumor cells from presence of specific stem-loop DNA molecules outside the nucleus, useful for diagnosis and monitoring of tumors | |
EP1090927A1 | Polypeptide (scFv) for the detection and removal of CA19-9 antigen positive cells | |
WO9940187A1 | Nucleic acids provided for modulating cellular activation | |
DE19859056A1 | New nucleic acids that inhibit expression of the CD30 antigen or ribosomal kinase rsk3, for modulating activity of, or killing, cells expressing these proteins, e.g. tumor cells | |
WO9918235A1 | Process for detecting, extracting or removing human or mammalian cells with a disturbed cellular cycle regulation or unlimited proliferation or tumour-forming ability | |
DE19640733A1 | Polypeptide than binds to CD30 without cell activation |